BYSI - BeyondSpring Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
16.33
+0.28 (+1.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.05
Open16.20
Bid16.27 x 3000
Ask16.34 x 1400
Day's Range15.77 - 16.45
52 Week Range13.06 - 26.98
Volume88,212
Avg. Volume67,231
Market Cap390.375M
Beta (3Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-2.12
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    BeyondSpring Announces Pricing of Public Offering of Ordinary Shares

    BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the pricing of its public offering of 2,058,825 ordinary shares at a public offering price of $17.00 per share. The offering was led by Decheng Capital. The gross proceeds from the public offering are expected to be $35.0 million, before deducting underwriting discounts and commissions and other offering expenses.

  • GlobeNewswire4 days ago

    BeyondSpring Announces Proposed Public Offering of Ordinary Shares

    BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced that it plans to launch an underwritten public offering of its ordinary shares. The offering is being led by Decheng Capital LLC. The Company also expects to grant the underwriter an option to purchase up to an additional 15% of the ordinary shares being offered to cover over-allotments. The Company intends to use the net proceeds of this offering to support continued clinical and pre-clinical development and for general corporate purposes.

  • GlobeNewswire10 days ago

    BeyondSpring Provides Operational Update and First Quarter 2019 Financial Results

    - New and Compelling Plinabulin Data Presented at Key Scientific Conferences - - To Submit New Drug Applications (NDAs) in China for Both Non-Small Cell Lung Cancer (NSCLC) and.

  • Benzinga22 days ago

    18 Stocks Joining The Russell Indices

    The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...

  • GlobeNewswirelast month

    BeyondSpring Set to Join FTSE Russell 3000® Index

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that it will join the FTSE Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the U.S. market opens on July 1, 2019, according to a preliminary list of additions posted June 7, 2019. Membership in the Russell 3000® Index, which remains in place for one year, means the automatic inclusion of BeyondSpring common stock in index funds designed to track stocks included in the Russell 3000® Index. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

  • GlobeNewswire2 months ago

    BeyondSpring to Present at the Jefferies 2019 Healthcare Conference

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the Jefferies 2019 Healthcare Conference in New York, NY on Friday, June 7, 2019, at 9:00 a.m. Eastern Time. BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).

  • GlobeNewswire2 months ago

    BeyondSpring Abstract Demonstrating Bone Pain Benefit with Lead Asset, Plinabulin, versus Neulasta for Neutropenia Prevention Presented at ISPOR 2019

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company’s abstract on its lead asset, Plinabulin, has been accepted for poster presentation at the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 2019 Conference. ISPOR is internationally recognized as the leading educational and scientific organization for health economics and outcomes research (HEOR) and its use in healthcare decisions. The data, derived from BeyondSpring’s Phase 2 Study 105, shows that Plinabulin at 20mg/m2 has a similar efficacy profile in reducing docetaxel-induced neutropenia as Neulasta 6mg (pegfilgrastim, the current standard of care), with the added safety benefit of avoiding the patient-reported bone pain that’s typically observed with Neulasta.

  • GlobeNewswire2 months ago

    BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that two of the Company’s abstracts on its lead asset, Plinabulin, have been accepted for publication in the Proceedings of this year’s ASCO Annual Meeting. The data, derived from BeyondSpring’s Phase 2 Study 106, provides a strong rationale for the Plinabulin Neulasta (pegfilgrastim) combination for the prevention of chemotherapy-induced neutropenia (CIN) for improved CIN control.

  • GlobeNewswire3 months ago

    BeyondSpring Files 2018 Annual Report on Form 20-F

    NEW YORK, April 30, 2019 -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that.

  • BeyondSpring Inc. (BYSI) Q4 2018 Earnings Call Transcript
    Motley Fool3 months ago

    BeyondSpring Inc. (BYSI) Q4 2018 Earnings Call Transcript

    BYSI earnings call for the period ending December 31, 2018.

  • GlobeNewswire3 months ago

    BeyondSpring Provides Business Update and Fourth Quarter and Full-Year 2018 Financial Results

    - Significant Clinical Data Generated for Plinabulin - - On Track to Submit New Drug Applications (NDAs) for Plinabulin to China’s National Medical Products Administration.

  • ACCESSWIRE3 months ago

    BeyondSpring, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 30, 2019 / BeyondSpring, Inc. (NASDAQ: BYSI ) will be discussing their earnings results in their 2018 Third Quarter Earnings to be held on April 30, 2019 at 8:00 AM Eastern ...

  • GlobeNewswire3 months ago

    BeyondSpring to Host Fourth-Quarter and Full-Year 2018 Financial Results and Operational Update Conference Call on April 30, 2019

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2018 financial results and host an operational and clinical update conference call on Tuesday, April 30, 2019, at 8:00 a.m. Eastern Time. BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).

  • GlobeNewswire4 months ago

    BeyondSpring to Present at the 18th Annual Needham Healthcare Conference

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 8:00 a.m. Eastern Time at the Westin Grand Central Hotel in New York, NY. BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).

  • GlobeNewswire4 months ago

    BeyondSpring’s Lead Asset, Plinabulin, Shifts the Balance of Macrophages Towards Anti-Cancer M1s

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present a promising new strategy for cancer treatment involving the ability of lead asset, Plinabulin, to positively shift the balance of macrophage phenotypes for beneficial anti-cancer effect at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia. The results will be highlighted in a poster presentation titled, “Microtubule Destabilization by Plinabulin Generates Anti-Tumor Immune Response through Repolarization of Intratumoral Macrophages,” taking place on April 3rd from 8 a.m. to 12 p.m. local time.

  • GlobeNewswire4 months ago

    BeyondSpring Advancing Patient Targeting Strategies for Lead Asset Plinabulin

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present novel data relevant to predictive biomarkers for patient selection for its lead asset, Plinabulin, at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia. The results from this non-clinical study will be highlighted in a poster presentation titled, “Predictive Models for Tumor Cell Targeting with Plinabulin, Derived from In Vitro Screening and Affymetrix mRNA Expression Data,” on April 1 from 8 a.m. to 12 p.m. local time.

  • GlobeNewswire4 months ago

    BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at 2019 St. Gallen International Breast Cancer Conference

    NEW YORK, March 20, 2019 -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that.

  • GlobeNewswire5 months ago

    BeyondSpring Presents New Promising Data in Chemotherapy-Induced Neutropenia at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, presented new clinical results from its Study 106 program in the prevention of chemotherapy induced neutropenia (CIN) for its lead asset Plinabulin at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The data showed that, through combining Plinabulin with Neulasta, patients not only experienced better outcomes for CIN treatment, but Neulasta’s potential immune-suppressive phenotype was also reduced.

  • GlobeNewswire5 months ago

    New Data Shows Addition of BeyondSpring’s Plinabulin Reverses Neulasta’s Potential Immune-Suppressive Phenotype in Treating Chemotherapy-Induced Neutropenia

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced new clinical results from its Study 106 program for lead asset Plinabulin, which demonstrates that combining Plinabulin with Neulasta (pegfilgrastim) not only improves overall efficacy for chemotherapy-induced neutropenia (CIN) treatment but also reverses Neulasta’s potential immune-suppressive phenotype. The data will be presented by Dr. Douglas Blayney, global Principal Investigator for BeyondSpring’s CIN development program and Professor of Medicine at Stanford University Medical Center, in a poster presentation titled, “A Phase II trial with the Combination of Plinabulin and Pegfilgrastim: Evaluation of the Reversal of Peg’s Immune-Suppressive Potential by the Addition of Plin to Peg,” at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.

  • GlobeNewswire7 months ago

    BeyondSpring Announces Positive Pre-NDA Meeting with the U.S. FDA for its Lead Asset, Plinabulin

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it had a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding its lead asset, Plinabulin. The focus of this meeting was the content of the chemistry, manufacturing and control (CMC) sections of the Company’s planned NDAs for Plinabulin for the treatment of non-small cell lung cancer (NSCLC) and chemotherapy-induced neutropenia (CIN) prevention.

  • GlobeNewswire7 months ago

    United States Patent and Trademark Office Issues Composition of Matter Patent with BeyondSpring’s Lead Asset Plinabulin with Protection to 2036

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company U.S. Patent No. 10,155,748 related to a new composition of matter of BeyondSpring’s lead asset, Plinabulin. This composition of matter patent is directed to Plinabulin’s monohydrate in a crystalline form and provides patent protection in the U.S. until 2036. “Adding yet another vital patent to BeyondSpring’s robust global intellectual property (IP) portfolio enables us to effectively maximize Plinabulin’s commercial potential across therapeutic indications, starting with chemotherapy-induced neutropenia (CIN) prevention and non-small cell lung cancer (NSCLC) treatment, followed by combinations with immunotherapies,” said Dr. Huang.

  • GlobeNewswire7 months ago

    BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Phase 3 portion of its pivotal Study 105, evaluating its lead asset, Plinabulin, in the 105 enrolled patients treated with docetaxel chemotherapy, has met its primary endpoint of non-inferiority versus Neulasta® for the duration of severe neutropenia (DSN) of the first cycle, with statistical significance in a pre-specified interim analysis. In this trial, Plinabulin as a single agent was compared head-to-head with Neulasta as a single agent.

  • GlobeNewswire7 months ago

    Data for BeyondSpring’s Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia (CIN) Prevention Shows Differentiated Profile Compared with G-CSF and Adds Additional Protection to G-CSF

    Plinabulin monotherapy is an equally effective single-dose-per cycle agent as pegfilgrastim, but with minimal bone pain vs. pegfilgrastim in intermediate neutropenic risk.

  • Can The Uptrend Continue for BeyondSpring (BYSI)?
    Zacks8 months ago

    Can The Uptrend Continue for BeyondSpring (BYSI)?

    Investors certainly have to be happy with BeyondSpring Inc. (BYSI) and its short term performance.